Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Cell Int
Hlavní autoři: Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Primary Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://ncbi.nlm.nih.gov/pubmed/30636931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0725-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky